New eczema drug enters Mid-Stage testing
NCT ID NCT07175233
Summary
This study aims to see if a new drug called SIM0278 can safely reduce the severity of moderate to severe eczema (atopic dermatitis) in adults. About 184 participants will be randomly assigned to receive one of three different doses of the drug or a placebo for 16 weeks. The main goal is to measure how much the drug reduces the extent and severity of the skin rash compared to the start of the study.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hangzhou First People's Hospital, School of Medicine , West Lake University
Hangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of China Medical University
Shenyang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.